Introduction/MDMA Therapy for PTSD | Neural Pharm

Introducing the Neural Pharm Podcast, featuring your hosts Colby Burns, PharmD, and Christopher Toney, PharmD. Episode 1 establishes the mission of the podcast, and covers the groundbreaking MAPP1 and MAPP2 trials that established MDMA as a breakthrough therapy for PTSD. We also cover key safety data including drug interactions, pharmacokinetics (or metabolism), and pharmacogenomics (or gene-drug interactions). Come join us!

 

***Correction Alert: The Ted talk referenced by Colby in the conclusion of the podcast was given by Dr. Ben Sessa, not Sassa (see the attached video in the reference section)****

References:

1. Mitchell J, et al. MDMA Assisted Therapy for Severe PTSD: A randomized, double blind, placebo controlled phase 3 study. Nature. 10 May 2021 <https://www.nature.com/articles/s41591-021-01336-3>

2. Mental Health By the Numbers. National Alliance on Mental Illness. 2023. <https://www.nami.org/mhstats>

3. Sessa B, et al. A Review of 3,4-methylenedioxymethamphetamine (MDMA) Assisted Psychotherapy. 2019(10). <https://www.frontiersin.org/articles/10.3389/fpsyt.2019.00138/full>

4. Sessa B. Is MDMA psychiatry’s antibiotic? Tedx University of Bristol. 5 July 2016.

5. Silverstone P. The Promise of Psychedelics: Science Based Hope for Better Mental Health. 2022 Apr 21. Ingenium books.